Student Research Committee, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Department of Dermatology, Skin Disease and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Dermatol Ther. 2020 Jul;33(4):e13733. doi: 10.1111/dth.13733. Epub 2020 Jun 26.
The world is facing a viral pandemic of a new coronavirus called COVID-19. Pentoxifylline is a methyl-xanthine derivative and it inhibits the phosphodiesterase IV (PDE IV). This drug is known for its unique features as an immunomodulatory and anti-inflammatory agent, also it could have antiviral affects. This is a scoping review, in which all related articles on COVID-19 and the probable benefits of Pentoxifylline against COVID-19 pathogenesis, in Medline, Scopus, Web of Sciences, and Google Scholar up to 20 March 2020 with proper keywords including: pentoxifylline, Pentoxil, COVID-19, coronavirus, treatment, anti-inflammatory, immunomodulatory, antifibrosis, oxygenation, circulation, bronchodilator, ARDS, and organ failure. We found many confirmatory data on proper efficacy of pentoxifylline on controlling COVID-19 and its consequences. The antiviral, anti-inflammatory, anti-oxidative, immune-modulatory, bronchodilator and respiratory supportive effects and protective roles in organ failures of PTX, along with its main functions means better circulation-oxygenation properties, low price and safety, make it a promising drug to be considered for COVID-19 treatment, especially as an adjuvant therapy in combination with other drugs.
世界正面临一种名为 COVID-19 的新型冠状病毒大流行。己酮可可碱是一种甲基黄嘌呤衍生物，可抑制磷酸二酯酶 4（PDE4）。该药具有独特的免疫调节和抗炎作用，也可能具有抗病毒作用。这是一项范围界定审查，其中包括截至 2020 年 3 月 20 日，在 Medline、Scopus、Web of Sciences 和 Google Scholar 上使用适当的关键字（包括：己酮可可碱、Pentoxil、COVID-19、冠状病毒、治疗、抗炎、免疫调节、抗纤维化、氧合、循环、支气管扩张剂、ARDS 和器官衰竭）搜索到的所有与 COVID-19 相关的文章和 Pentoxifylline 对 COVID-19 发病机制的可能益处。我们发现了许多关于己酮可可碱控制 COVID-19 及其后果的适当疗效的确认数据。PTX 的抗病毒、抗炎、抗氧化、免疫调节、支气管扩张和呼吸支持作用及其在器官衰竭中的保护作用，以及其主要功能意味着更好的循环-氧合特性、低廉的价格和安全性，使其成为一种有前途的药物，可以考虑用于 COVID-19 治疗，特别是作为联合其他药物的辅助治疗。
